FDA clears Lumvoa for thyroid eye disease as AI limits emerge

FDA approval headlines busy month for ophthalmology

The FDA cleared veligrotug-vvze (Lumvoa) for thyroid eye disease in late June 2026, marking the first approved therapy that addresses both active and chronic disease stages. The 12-week intravenous regimen delivered rapid improvements in proptosis and diplopia, according to Ophthalmology Times.

The approval capped a month dense with regulatory and pipeline activity. The FDA accepted Outlook Therapeutics' resubmitted biologics license application for ONS-5010 (LYTENAVA), setting a July 29, 2026 target action date. Belite Bio completed its rolling new drug application for tinlarebant, which would become the first approved treatment for Stargardt disease type 1 if cleared. Meanwhile, NCX 470 received positive regulatory feedback in China ahead of a planned U.S. submission for glaucoma.

Retina research and rare disease trials advance

A preference study led by Csaky found that U.S. retina specialists prioritize lesion growth rate reduction when selecting geographic atrophy treatments, showing higher risk tolerance for foveal-threatening lesions. On the funding side, Memento Medicines launched with $93 million in Series A capital to advance MMT-205, a bispecific antibody targeting both Tie2 activation and VEGF inhibition, toward first-in-human trials in 2027.

Two phase 3 trials began enrolling patients in June. Atsena dosed its first patient in the pivotal cohort of the LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis. Alkeus Pharmaceuticals started the NORTHSTAR trial of oral gildeuretinol for Stargardt disease.

AI performance falls short in surgical prediction and subspecialty tasks

Artificial intelligence tools showed clear limits in clinical ophthalmology applications during June. A study found ChatGPT-5 overpredicts success rates after macular hole surgery, outperforming human specialists on paper while missing actual failures in practice.

Training methodology emerged as critical. Researchers reported that balanced datasets combining AI-generated and smartphone-captured images eliminated domain-specific failures seen when models trained on single image sources. Prompt engineering also mattered: step-by-step reasoning prompts improved multimodal AI accuracy on bilingual ophthalmology vignettes that included images, though weak performance persisted in subspecialty knowledge and image interpretation.

One bright spot appeared in Alzheimer's research, where optical coherence tomography angiography revealed distinctive microvascular signatures in retinal layers associated with cognitive decline stages.

Glaucoma and anterior segment studies deliver real-world data

A large cohort study linked obstructive sleep apnea with elevated glaucoma risk, though researchers could not determine whether positive airway pressure therapy affects outcomes. A retrospective analysis of 218 eyes found direct selective laser trabeculoplasty significantly lowered intraocular pressure, with the greatest benefit in treatment-naive patients.

In corneal work, a prospective pilot series showed Keraring implantation reduced refractive cylinder by 61% in non-ectatic corneas, potentially expanding intracorneal ring segment indications. A case report described successful treatment of corneal epithelial downgrowth using image-guided excision, cryotherapy, and a single anterior chamber methotrexate injection, with no recurrence at 10 months. Dompé initiated the phase 3 Orunea trial of cenegermin-bkbj for persistent corneal epithelial defects.

Why it matters

The convergence of new approvals, maturing gene therapy pipelines, and honest assessments of AI limitations signals a maturation phase for ophthalmology innovation. While regulatory momentum continues in rare diseases and novel mechanisms, the gap between AI's theoretical performance and clinical utility highlights the need for rigorous validation before deployment. For health systems evaluating AI tools, June's data underscores that algorithmic sophistication does not guarantee clinical accuracy.

Device and industry moves

Bayer acquired Perfuse Therapeutics and its endothelin-blocking implant PER-001, while partnering with AI firm Iambic to accelerate small-molecule discovery. Heidelberg Engineering received FDA clearance for new SPECTRALIS software featuring 250 kHz OCT angiography scan speed and enhanced eye tracking. The TECNIS PureSee intraocular lens launched in the U.S. following FDA approval.

These developments were first reported by Ophthalmology Times in their June 2026 roundup.